ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS.
Our therapeutic programs modulate the natural protective, reparative and regenerative pathways of the body in both orphan diseases and larger clinical indications.
Our robust pre-clinical and clinical portfolio targets areas of high unmet medical need across a spectrum of therapeutic indications, including acute kidney injury (AKI) and chronic kidney disease (CKD).
ANGION’S MISSION is
to deliver effective therapies that heal injured organs and save lives.
Angion Awarded $4.76 Million Department of Defense Grant for Chronic Kidney Disease Drug Candidate ANG-3070
Angion Completes Equity Financing and Appoints Senior Executives
Angion Biomedica to present at Piper Jaffray Healthcare Conference